Key result
Heart rate control management using a beta-lactam dosing regimen in post-PCI STEMI patients achieved a clinical efficacy rate of 95.65% and a predictive sensitivity of 95.29%.
Why the study?
Post-PCI STEMI patients may experience reduced perfusion capacity and myocardial injury, but few studies have focused on the clinical impact of heart rate control management post-PCI.
Do different heart rate control administration programs improve clinical response, TIMI flow, and myocardial injury in post-PCI STEMI patients?
Do different heart rate control administration programs improve clinical response, TIMI flow, and myocardial injury in post-PCI STEMI patients?
Heart rate control management using different stages of a beta-lactam dosing regimen was reported to improve clinical efficacy and reduce myocardial injury in post-PCI STEMI patients, though the mention of beta-lactams for heart rate control suggests a likely error in the source text.
Answers are grounded in this paper and cite their sources.
May support beta-lactam dosing for post-PCI STEMI heart rate control; hypothesis-generating and leaves open randomized validation.
Post-PCI STEMI patients may suffer from reduced perfusion capacity and myocardial injury, and few existing studies have focused on the role of heart rate control management in the clinical impact of post-PCI. In this paper, we first selected post-PCI STEMI patients as an example, given specific inclusion and exclusion criteria, and conducted controlled experiments through heart rate stability testing with different heart rate control administration programs. Secondly, linear regression combined with the SCAD penalty function was utilized for the screening of clinical impact variables in post-PCI STEMI patients. Finally, the clinical response, TIMI flow classification and myocardial injury of STEMI patients after PCI were analyzed, and the clinical influencing factors of STEMI patients were fully explored by combining ROC curve with linear regression. The results showed that the total effective rate of clinical efficacy in the MACE group was 95.65%, the significance test result of TIMI flow classification was 0.012, and myocardial injury indexes showed significant differences at 1% level after different stages of the beta-lactam dosing regimen. The predictive sensitivity in the MACE group was 95.29%, and its 95% confidence interval was 0.882~0.945. The number of high risks in the linear regression decreased almost 9-fold when the threshold of LogP was increased from 0 to 0.4. The management of heart rate control in post-PCI STEMI patients can be effectively achieved by different stages of the beta-lactam dosing regimen, and the negative impact on STEMI patients after PCI can be reduced.
No takes yet. Share an insight, caveat, or question.
Du et al. (2023) studied STEMI after percutaneous coronary intervention (PCI). beta-lactam dosing regimen was evaluated on clinical efficacy and predictive sensitivity in the MACE group (predictive sensitivity 95.29%, 95% CI 0.882-0.945, p=0.012). Heart rate control management using a beta-lactam dosing regimen in post-PCI STEMI patients achieved a clinical efficacy rate of 95.65% and a predictive sensitivity of 95.29%.
Synapse has enriched 10 related papers. Consider them for comparative context: